10 not yet recruiting, 4 recruiting, 1 active not recruiting. 10 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Not yet recruiting 6, Recruiting 4 |
| Phase 3 | 3 | Not yet recruiting 2, Active not recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Benmelstobart: new trials by email Literature Review of Benmelstobart trials Research Report on Benmelstobart
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 214 | 2026-12-01 | 2026-10-29 |
| Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC Benmelstobart, benmelstobart combined with chemotherapy and anlotinib - NSCLC | Phase 2 | Not yet recruiting | The Third Xiangya Hospital of Central South University | 152 | 2026-05-15 | 2026-06-11 |
| A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer benmelstobart, Anlotinib, Carboplatin or cisplatin - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 33 | 2026-04-20 | 2026-04-20 |
| Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Benmelstobart, SBRT, Anlotinib - Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 29 | 2026-04-20 | 2026-04-17 |
| Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer Benmelstobart, Anlotinib, Cisplatin or carboplatin - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 2 | Not yet recruiting | Yayi He | 27 | 2026-04-20 | 2026-04-20 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma Benmelstobart, Anlotinib, Sunitinib - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 126 | 2025-06-01 | 2026-10-20 |
| Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations Icotinib, Rezivertinib, Ensartinib - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 270 | 2025-05-01 | 2025-05-06 |
| Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Benmelstobart, Anlotinib, Carboplatin or cisplatin - Extensive-stage Small Cell Lung Cancer | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 50 | 2025-04-15 | 2025-04-23 |
| Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC Benmelstobart, Anlotinib, Cisplatin - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 45 | 2024-12-03 | 2024-11-21 |
| The Efficacy and Safety of Benmelstobart for GC/EGC surgery, Benmelstobart, tegafur - Gastric Cancer | Not applicable | Not yet recruiting | Xijing Hospital | 48 | 2024-10-16 | 2024-09-19 |
| Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma Benmelstobart - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 62 | 2024-06-05 | 2024-07-31 |
| Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) Golidocitinib, Benmelstobart - Natural Killer T-cell Lymphoma | Phase 2 | Recruiting | Sun Yat-sen University | 47 | 2024-01-27 | 2025-02-10 |
| A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study LM-302, Toripalimab, Capecitabine - Malignant Neoplasms of Digestive Organs | Phase 2 | Recruiting | LaNova Medicines Zhejiang Co., Ltd. | 632 | 2023-07-27 | 2026-10-19 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
Small Cell Lung Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Nasopharyngeal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Sun Yat-sen University (4) · Yayi He (2) · Fudan University (1) · LaNova Medicines Zhejiang Co., Ltd. (1) · Nanfang Hospital, Southern Medical University (1) · Peking Union Medical College Hospital (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · The Third Xiangya Hospital of Central South University (1) · Xijing Hospital (1)
China (9)
Aiping Zhou (1) · Chang Chen, MD, PhD (1) · Chen Jinzhang (1) · Chunmei Bai (1) · Deliang Fu (1) · Deping Zhao, MD, PhD (1) · Haijiao Yan (1) · Haiping Jiang (1) · Jieer Ying (1) · Jin Li (1) · Jing Dai (1) · Jun Ma, M.D. (1) · Jun Zhou (1) · Kuirong Jiang (1) · Liang Liu (1)
PMID 34673888, PMID 35143424, PMID 37574133, PMID 38362377, PMID 38572751, PMID 42857095